97 results on '"Frost, Adaani E."'
Search Results
52. Breathing by Double-Lung Recipients during Exercise: Response to Expiratory Threshold Loading
53. Hyperacute Rejection Following Lung Transplantation*
54. Bronchiolitis Obliterans in Recipients of Single, Double, and Heart-Lung Transplantation*
55. Outcome of the Native Lung After Single Lung Transplant*
56. Giant Cell Interstitial Pneumonitis: Disease Recurrence in the Transplanted Lung
57. Inadvertent reuse of bronchoscope used on AIDS patient in lung-transplant recipient without sterilisation
58. Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry
59. Early clearance vs persistence of de novo donor-specific antibodies following lung transplantation
60. Longitudinal change in pulmonary arterial capacitance as an indicator of prognosis and response to therapy and in pulmonary arterial hypertension
61. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study
62. Severe ischemic injury to the proximal airway following lung transplantation: immediate and long-term effects on bronchial cartilage
63. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial
64. The Intersection of Pulmonary Hypertension and Solid Organ Transplantation
65. Navigating the Road to Transplant in Pulmonary Arterial Hypertension: A Road Less Taken
66. Validation of two predictive models for survival in pulmonary arterial hypertension
67. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
68. Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension
69. Validation Of The French Pulmonary Hypertension Network Equation To Estimate Survival: A REVEAL Analysis
70. Can Pulmonary Arterial Hypertension Be Diagnosed by an Elevated Pulmonary Capillary Wedge Pressure Outside of the Guideline Criteria?: Response
71. REVEAL Registry: Impact of Clinical Worsening on Three-Year Outcomes in Pulmonary Arterial Hypertension
72. PROGNOSTIC VALUE OF HEART RATE AND SYSTEMIC BLOOD PRESSURE IN PULMONARY ARTERIAL HYPERTENSION
73. Pulmonary Arterial Hypertension
74. Pulmonary Hypertension and Lung Transplantation, 2010
75. REVEAL REGISTRY: EFFECT OF HISTORY OF ANOREXIGEN USE ON OUTCOMES OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
76. Interventional and Surgical Modalities of Treatment in Pulmonary Hypertension
77. A COMPARISON OF REVEAL REGISTRY DEMOGRAPHIC DATA WITH OTHER/PRIOR REGISTRIES OF PULMONARY ARTERIAL HYPERTENSION (PAH)
78. AMBRISENTAN RESCUE THERAPY IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION WHO DISCONTINUED BOSENTAN OR SITAXSENTAN DUE TO LIVER FUNCTION ABNORMALITIES
79. Ambrisentan Therapy for Pulmonary Arterial Hypertension
80. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol
81. Dysregulation of BMPR2, Arginase II and HMGA2 Expression in Idiopathic Myelofibrosis and Secondary Myelofibrosis.
82. Sitaxsentan Sodium for the Treatment of Pulmonary Hypertension (PAH) in Patients Failing Bosentan: Preliminary Single Center Data
83. Correlation of change in 6MWT and NYHA functional class in patients with pulmonary arterial hypertension (PAH)
84. End points and clinical trial designs in pulmonary arterial hypertension
85. GUIDELINES FOR THE REFERRAL AND MANAGEMENT OF PATIENTS ELIGIBLE FOR SOLID ORGAN TRANSPLANTATION
86. INTERNATIONAL GUIDELINES FOR THE SELECTION OF LUNG TRANSPLANT CANDIDATES
87. PLASMA CATECHOLAMINE LEVELS IN END-STAGE LUNG DISEASE: A POTENTIAL MARKER OF DISEASE SEVERITY
88. DONOR CRITERIA AND EVALUATION
89. Giant Cell Interstitial Pneumonitis: Disease Recurrence in the Transplanted Lung
90. A prospective echocardiographic evaluation of pulmonary hypertension in chronic hemodialysis patients in the United States: prevalence and clinical significance.
91. Development of prognostic tools in pulmonary arterial hypertension: Lessons from modern day registries
92. End points and clinical trial designs in pulmonary arterial hypertension Clinical and regulatory perspectives
93. Can Pulmonary Arterial Hypertensio Be Diagnosed by an Elevated Pulmonary Capillary Wedge Pressure Outside of the Guideline Criteria?
94. Dysregulation of BMPR2, Arginase IIand HMGA2Expression in Idiopathic Myelofibrosis and Secondary Myelofibrosis.
95. PLASMA CATECHOLAMINE LEVELS IN ENDSTAGE LUNG DISEASE A POTENTIAL MARKER OF DISEASE SEVERITY
96. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial
97. Long-term safety and efficacy of imatinib in pulmonary arterial hypertension
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.